Monitor Scilex's ability to meet the July 31 and September 30 payment deadlines. Stock settlement alternative introduces dilution risk for Scilex but provides Oramed with a recovery path. The bylaw changes are neutral.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $4.61entry
- T+1 · 5mo ago −0.22%α −0.09% · $4.60
- T+5 · 4mo ago −6.72%α −6.99% · $4.30
- T+20 · 4mo ago −13.88%α −11.70% · $3.97
- T+60 · 8w ago +3.90%α +1.03% · $4.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oramed Pharmaceuticals extended payment obligations from Scilex Holding Company, covering approximately $29.5M Tranche A Note and $6.7M Tranche B Note. Scilex agreed to pay $0.5M immediately and the remaining balance by September 30, 2026, with stock settlement if default occurs. The bylaw amendments are routine governance changes.
Key Facts
- Extension agreement with Scilex for outstanding notes: Tranche A ~$29.5M, Tranche B ~$6.7M as of June 30, 2026
- Scilex paid $0.5M on June 25, 2026; further $5M due by July 31, 2026; full balance by September 30, 2026
- If Scilex defaults, first $1.5M retained as fee and remaining obligations may be settled with Scilex common stock
- Bylaws amended to simplify record date procedures for stockholder action by written consent and tighten consent delivery timeline
Financial Impact
Total outstanding obligations of approximately $36.2M, representing ~19% of Oramed's market cap. Cash received $0.5M, with $5M due in July and remainder by September.
Risk Factors
- Scilex may fail to make future payments, forcing stock settlement or litigation
- If stock settlement occurs, Oramed could receive shares of a potentially distressed issuer
- No guarantee that full principal and interest will be recovered
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-073709 |
| Document: ea0296520-8k_oramed.htm | 0001213900-26-073709 |
| Document: 0001213900-26-073709-index-headers.html | 0001213900-26-073709 |
| Document: 0001213900-26-073709-index.html | 0001213900-26-073709 |
| Document: 0001213900-26-073709.txt | 0001213900-26-073709 |
Track record
4 reports on ORMP
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $4.03 Now $3.90 −3.23% settles Dec 15
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $4.55 to $4.11 Now $3.90 −14.29% ▼ −9.67% −7.20% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 4/10 Entry $4.60 to $4.12 Now $3.90 −15.22% ▼ −10.43% −10.02% vs SPY
- Jun 30, 202619w ago 8-K Mixed 5/10 Viewing Entry $4.61 to $3.97 Now $3.90 −15.40% ▼ −13.88% −11.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers